1.Executive Summary
2.Research Objectives
3.Research Focus
3.1 The ‘multiple’ hit hypothesis for NASH pathogenesis
4.Current Treatments
4.1 Overview
5.Vitamin E
5.1 Key insights summary
5.2 Drug summary
6.Actos/Glustin (pioglitazone; Takeda/Eli Lilly)
6.1 Key insights summary
6.2 Drug summary
7.Pipeline Drugs
7.1 Overview
8.Obeticholic acid (OCA/Ocaliva; Intercept Pharmaceuticals)
8.1 Key insights summary
8.2 Drug summary
9.Elafibranor (GFT505; Genfit Pharmaceuticals)
9.1 Key insights summary
9.2 Drug summary
10.Cenicriviroc (CVC; Tobira Therapeutics/Allergan)
10.1 Key insights summary
11.Selonsertib (GS-4997; Gilead)
11.1 Key insights summary
11.2 Drug summary
12.Aramchol (Galmed Pharmaceuticals)
12.1 Key insights summary
12.2 Drug summary
13.Emricasan (IDN-6556; Conatus Pharmaceuticals/Novartis)
13.1 Key insights summary
14.GR-MD-02 (Galectin Therapeutics)
14.1 Key insights summary
14.2 Drug summary
15.Semaglutide (Novo Nordisk)
15.1 Key insights summary
15.2 Drug summary
16. IVA337 (Inventiva)
16.1 Key insights summary
16.2 Drug summary
17. LJN452 (Novartis)
17.1 Key insights summary
17.2 Drug summary
18. Volixibat (SHP 626; Shire/Sanofi)
18.1 Key insights summary
18.2 Drug summary
19.BMS-986036 (Bristol-Myers Squibb)
19.1 Key insights summary
19.2 Drug summary
20. Future developments in NASH
20.1 Key insights summary
21. Current and future treatment algorithm
22. Conclusion
23. Appendix
23.1 KOL biographies